Current and novel biomarkers of thrombotic risk in COVID-19: a consensus statement from the international COVID-19 thrombosis biomarkers colloquium
Abstract Coronavirus disease 2019 (COVID-19) predisposes patients to thrombotic and
thromboembolic events, owing to excessive inflammation, endothelial cell activation and …
thromboembolic events, owing to excessive inflammation, endothelial cell activation and …
Immunity, endothelial injury and complement-induced coagulopathy in COVID-19
In December 2019, a novel coronavirus was isolated from the respiratory epithelium of
patients with unexplained pneumonia in Wuhan, China. This pathogen, named severe acute …
patients with unexplained pneumonia in Wuhan, China. This pathogen, named severe acute …
[HTML][HTML] Coagulopathy in COVID‐19
The COVID‐19 pandemic has become an urgent issue in every country. Based on recent
reports, the most severely ill patients present with coagulopathy, and disseminated …
reports, the most severely ill patients present with coagulopathy, and disseminated …
Cerebrospinal fluid findings in COVID-19: a multicenter study of 150 lumbar punctures in 127 patients
S Jarius, F Pache, P Körtvelyessy, I Jelčić… - Journal of …, 2022 - Springer
Background Comprehensive data on the cerebrospinal fluid (CSF) profile in patients with
COVID-19 and neurological involvement from large-scale multicenter studies are missing so …
COVID-19 and neurological involvement from large-scale multicenter studies are missing so …
The case of complement activation in COVID-19 multiorgan impact
The novel coronavirus disease COVID-19 originates in the lungs, but it may extend to other
organs, causing, in severe cases, multiorgan damage, including cardiac injury and acute …
organs, causing, in severe cases, multiorgan damage, including cardiac injury and acute …
Eculizumab as an emergency treatment for adult patients with severe COVID-19 in the intensive care unit: a proof-of-concept study
D Annane, N Heming, L Grimaldi-Bensouda… - …, 2020 - thelancet.com
Background Complement pathway inhibition may provide benefit for severe acute
respiratory illnesses caused by viral infections such as COVID-19. We present results from a …
respiratory illnesses caused by viral infections such as COVID-19. We present results from a …
Endothelial dysfunction in COVID-19: lessons learned from coronaviruses
E Gavriilaki, P Anyfanti, M Gavriilaki, A Lazaridis… - Current hypertension …, 2020 - Springer
Abstract Purpose of Review To review current literature on endothelial dysfunction with
previous coronaviruses, and present available data on the role of endothelial dysfunction in …
previous coronaviruses, and present available data on the role of endothelial dysfunction in …
Invited Review: The spectrum of neuropathology in COVID‐19
S Al‐Sarraj, C Troakes, B Hanley… - Neuropathology and …, 2021 - Wiley Online Library
There is increasing evidence that patients with Coronavirus disease 19 (COVID‐19) present
with neurological and psychiatric symptoms. Anosmia, hypogeusia, headache, nausea and …
with neurological and psychiatric symptoms. Anosmia, hypogeusia, headache, nausea and …
Involvement of the nervous system in SARS-CoV-2 infection
H Li, Q Xue, X Xu - Neurotoxicity research, 2020 - Springer
As a severe and highly contagious infectious disease, coronavirus disease 2019 (COVID-
19) has caused a global pandemic. Several case reports have demonstrated that the …
19) has caused a global pandemic. Several case reports have demonstrated that the …
Pathology and pathogenesis of severe acute respiratory syndrome
J Gu, C Korteweg - The American journal of pathology, 2007 - Elsevier
Severe acute respiratory syndrome (SARS) is an emerging infectious viral disease
characterized by severe clinical manifestations of the lower respiratory tract. The …
characterized by severe clinical manifestations of the lower respiratory tract. The …